Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial)

Douglas E Gladstone, Christopher Howard, Mi-Ae Lyu, Jason Mock, Darryl Adams, Kevin Gibbs, Li Li, Meixian Huang, Ke Zeng, Franco D'Alessio, James Herlihy, Sergio Trevino, Parameswaran Hari, Tara Sadeghi, Simrit Parmar, Arthur Slutsky, Siddhartha Mukherjee

Blood (2021) 138 (Supplement 1): 828.

https://doi.org/10.1182/blood-2021-153616

Published: 2021

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Bryan Hambley, MD, Eric Gehrie, Jonathan Webster, MD, Margaret M. Showel, MD, Lukasz P. Gondek, MD PhD, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Douglas E Gladstone, MD, Ivana Gojo, MD, Gabriel Ghiaur, MD PhD, Keith W. Pratz, MD, B. Douglas Smith, MD, Amy E. DeZern, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 3841.

https://doi.org/10.1182/blood-2019-123229

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Cole Sterling, MD, Nina D. Wagner-Johnston, MD, Douglas E Gladstone, MD, Richard F. Ambinder, MD, Lode J. Swinnen, MB ChB, Philip Hollingsworth Imus, MD

Blood (2019) 134 (Supplement_1): 3342.

https://doi.org/10.1182/blood-2019-126253

Published: 2019

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Clio E Franklin, MBBS, BSc, MRCP, Margaret M. Showel, MD, Hua-Ling Tsai, ScM, Ravi Varadhan, PhD, Shannon R. McCurdy, MD, Douglas E. Gladstone, MD, Richard J. Jones, MD, Amy E. DeZern, MD

Blood (2017) 130 (Supplement 1): 849.

https://doi.org/10.1182/blood.V130.Suppl_1.849.849

Published: 2017

Journal Articles

Immunoglobulin Heavy Chain Variable Region (IgHV) Unmutated, but Not Mutated, Chronic Lymphocytic Leukemia (CLL) Arises in a CD34+ Progenitor

Brandy Perkins, Margaret M. Showel, MD, Laura Schoch, MS, NP, Philip Imus, MD, Gabriel Ghiaur, MD PhD, Douglas E. Gladstone, MD, Richard J. Jones, MD

Blood (2017) 130 (Supplement 1): 1709.

https://doi.org/10.1182/blood.V130.Suppl_1.1709.1709

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua-Ling Tsai, Javier Bolaños-Meade, Christopher G. Kanakry, Douglas E. Gladstone, Leo Luznik, Carol Ann Huff, Lode J. Swinnen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs, Yvette L. Kasamon

Blood (2014) 124 (21): 680.

https://doi.org/10.1182/blood.V124.21.680.680

Published: 2014

Journal Articles

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice M. Davis-Sproul, Nilanjan Ghosh, Heather J. Symons, MD, MHS, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

Blood (2012) 120 (21): 3084.

https://doi.org/10.1182/blood.V120.21.3084.3084

Published: 2012

Journal Articles

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Yvette L. Kasamon, Richard J. Jones, Christopher D. Gocke, Javier Bolaños-Meade, Lode J. Swinnen, Amanda Blackford, Douglas E. Gladstone, Ephraim J. Fuchs, Richard F. Ambinder

Blood (2012) 120 (21): 3107.

https://doi.org/10.1182/blood.V120.21.3107.3107

Published: 2012

Journal Articles

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie L. Popplewell, Thomas M. Habermann, Joseph M. Herman, William H. Matsui, Richard J. Jones, Richard F. Ambinder

Blood (2012) 119 (18): 4129–4132.

https://doi.org/10.1182/blood-2012-01-402792

Published: 2012

Journal Articles

Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.

B. Douglas Smith, MD, William H. Matsui, MD, Douglas E. Gladstone, MD, Judith E. Karp, MD, Steven D. Gore, MD, Carol Ann Huff, MD, Milada Vala, Sharyn Baker, MD, Ming Zhao, PhD, Steven Piantadosi, MD, Richard J. Jones, MD

Blood (2005) 106 (11): 2792.

https://doi.org/10.1182/blood.V106.11.2792.2792

Published: 2005

NARROW

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial)

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Immunoglobulin Heavy Chain Variable Region (IgHV) Unmutated, but Not Mutated, Chronic Lymphocytic Leukemia (CLL) Arises in a CD34+ Progenitor

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A -158 Polymorphism Over HLA Matching.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only